New York, NY -- (SBWire) -- 05/07/2019 --Biosimilars are bio-medical products that are identical copies of an original pharmaceutical drug, which has been manufactured by a different manufacturing company. Biosimilars are manufactured once the patent of the original product expires. Unlike generic drugs, biosimilars exhibit high molecular complexity and are sensitive to alterations in the processes of manufacturing. These drugs are similar to reference products, in terms of purity, safety and potency.
Request For Free Sample: @ https://www.marketindustryreports.com/pdf/67
The global biosimilars market is driven by cost effectiveness of drug due to which there is a increase demand of biosimilar drugs. Moreover, diverse applications of biosimilars for treatment of several chronic ailments, namely cancer and diabetes is anticipated to further contribute significantly to growing demand of this products in the coming years. Furthermore the collaboration are in a strategic manner which result in enhanced productivity and clinical trials. However, availability of affordable generic drugs, and complexity involved in the process of manufacturing are likely to restrain the market to a certain extent.
The global biosimilars market is segmented by product, type of manufacturing, diseases, and region. On the basis of product, the biosimilars market can be segmented into recombinant glycosylated proteins, recombinant non-glycosylated proteins, and recombinant peptides. The segment of recombinant glycosylated proteins can be further segmented into monoclonal antibodies, erythropoietin, and follitropin. The monoclonal antibodies can be segmented into rituximab, adalimumab, and infliximab. The segment of recombinant non-glycosylated proteins can be classified into insulin, granulocyte colony stimulating factor, recombinant human growth hormone and interferon. The interferon can be further bifurcated into interferon-alpha and interferon-beta. Finally, the segment of recombinant peptides can be segmented into glucagon and calcitonin. The recombinant non-glycosylated proteins segment accounted for the largest market share in the global biosimilars market, owing to its wide range of therapeutic applications On the basis of type of manufacturing, the market can be segmented into in-house manufacturing and contract manufacturing. In terms of market share, the segment of in-house manufacturing accounted for the largest share, as in-house manufacturing reduces costs associated with shipping, delivery and thereby lowering the overall cost of manufacturing. Similarly, in terms of diseases the biosimilars market can be segmented into chronic disease, oncology, autoimmune disease, blood disorders, infectious diseases, growth hormone deficiency and other diseases. The blood disorder segment accounted for the largest share of the market, owing to low cost of biosimilars as compared to biologics, and rising incidence of blood disorders worldwide among others.
Buy Now: @ https://www.marketindustryreports.com/checkout/67
The global biosimilars market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). Europe dominated the market of biosimilars market, followed by North America and Asia Pacific. Asia Pacific is expected to dominate the global biosimilars market in the forecast period. Factors such as the patent expiry of launch of new biosimilars, biologic products, rising incidence of chronic disorders, and emergence of new market players are anticipated to drive market growth in this region
Table of Contents
1. INTRODUCTION
1.1. Market Definition
1.2. Market Ecosystem
1.2.1. Market Classification
1.2.2. Geographic Scope
1.2.3. Years Considered for the Study: Historical Years – 2016 & 2017; Base Year – 2018; Forecasted Years – 2019 to 2030
1.3. Currency Used
2. RESEARCH METHODOLOGY
2.1. Research Framework
2.2. Data Collection Technique
2.3. Data Sources
2.3.1. Secondary Sources
2.3.2. Primary Sources
2.4. Market Estimation Methodology
2.4.1. Bottoms Up Approach
2.4.2. Top Down Approach
2.5. Data Validation and Triangulation
2.5.1. Market Forecasting Model
2.5.2. Limitations/Assumptions of the Study
3. ABSTRACT OF THE STUDY
4. MARKET DYNAMICS ASSESMENT
4.1. Overview
4.2. Drivers
4.3. Barriers/Challenges
4.4. Opportunities
5. UNIQUE SELLING PROPOSITIONS (USPs)
5.1. Regulatory Landscape Assessment
5.2. Pipeline Assessment
5.3. Epidemiological Assessment: Oncology
About Market Industry Reports
Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.
We continue to pioneer state-of-the-art approach in research & analysis that makes complex world simpler to stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence we bring proficient contingency to our clients in the evolving world of technologies, megatrends and industry convergence. We empower and inspire Vanguards to fuel and shape their business to build and grow world-class consumer products.
Contact Us-
502, Sai Radhe, Kennedy Road,
Behind Hotel Sheraton Grand,
Near Pune Station, Pune 411 001
Email: sales@marketindustryreports.com
Phone: + 91 9673535933
Website: https://www.marketindustryreports.com/
Follow Us- LinkedIn | Twitter | Google+ | Face book
Global Biosimilars Market 2019-2030 Industry Evolution Facts and Figures
The recent report, biosimilars market fundamentally discovers insights that enable stakeholders, business owners and field marketing executives to make effective investment decisions driven by facts – rather than guesswork.